What measures should be in place for investigational products in clinical trials?

• A. Measures to ensure that the investigational product retains its quality.
• B. Measures to minimize cost only.
• C. Measures to accelerate recruitment.
• D. Measures to avoid regulatory oversight.

Answer: (A)

Maintaining investigational product quality throughout its lifecycle is essential. This ensures patient safety and the integrity of trial data, and it aligns with regulatory expectations for how an investigational product is manufactured, stored, handled, and tracked. Measures should cover every step from manufacturing and packaging to storage, distribution, dispensing, administration, and eventual destruction or return of unused product. Key elements include validated manufacturing processes, proper batch release, accurate labeling and packaging, defined storage conditions with temperature control, secure receipt and chain-of-custody, complete inventory reconciliation, and proper destruction of leftovers. There must be a plan for handling deviations or recalls, with an auditable trail of investigations and corrective actions. A formal quality assurance system provides ongoing oversight, including quality control testing, supplier qualification, and routine inspections of processes and documentation. Thorough documentation and records retention ensure transparency and enable regulatory inspection. All of these practices protect participant safety and support reliable, credible trial results. Focusing solely on cost, speeding recruitment, or trying to avoid regulatory oversight would compromise safety and data integrity and violate GCP requirements.